Genelux Corp
GNLX5.300USD
-2.540-32.40%
收盘 11/06, 16:00（美东）报价延迟15分钟
197.83M总市值
亏损市盈率 TTM
关于 Genelux Corp 公司
Genelux Corporation 是一家处于临床后期的生物制药公司。该公司专注于为患有侵袭性和/或难以治疗的实体肿瘤类型的患者开发下一代溶瘤病毒免疫疗法。其临床和临床前候选产品旨在选择性杀死肿瘤细胞并诱导针对患者肿瘤新抗原的强大免疫反应。其候选产品 Olvi-Vec (olvimulogene nanivacirepvec) 是一种专有的改良痘苗病毒 (VACV) 菌株，这是一种具有强大工程能力的稳定脱氧核糖核酸 (DNA) 病毒。Olvi-Vec 是根据临床前研究的结果开发的，用于治疗多种癌症，这些研究表明 Olvi-Vec 有可能在体外和体内感染并直接杀死多种肿瘤细胞类型并产生抗肿瘤免疫反应。其产品组合还包括溶瘤痘苗免疫疗法临床候选药物。
Genelux Corp简介
公司代码GNLX
公司名称Genelux Corp
上市日期Jan 26, 2023
CEOMr. Thomas Zindrick, J.D.
员工数量24
证券类型Ordinary Share
年结日Jan 26
公司地址2625 Townsgate Road, Suite 230
城市WESTLAKE VILLAGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编91361
电话18052679889
网址https://genelux.com/
公司代码GNLX
上市日期Jan 26, 2023
CEOMr. Thomas Zindrick, J.D.
Genelux Corp公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Zindrick, J.D.
Mr. Thomas Zindrick, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
653.29K
+123.66%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
502.78K
+4.64%
Dr. Joseph Cappello, Ph.D.
Dr. Joseph Cappello, Ph.D.
Chief Technical Officer
Chief Technical Officer
138.02K
+352.27%
Ms. Mary Mirabelli
Ms. Mary Mirabelli
Independent Director
Independent Director
74.28K
+42.85%
Mr. John W. Smither
Mr. John W. Smither
Independent Director
Independent Director
70.38K
+46.33%
Mr. James L. (Jim) Tyree
Mr. James L. (Jim) Tyree
Lead Independent Director
Lead Independent Director
68.07K
+48.66%
Mr. Ralph Smalling
Mr. Ralph Smalling
Head - Regulatory
Head - Regulatory
54.76K
+22.34%
Mr. Eric Groen
Mr. Eric Groen
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
--
--
Dr. Tony Yu, Ph.D.
Dr. Tony Yu, Ph.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Mr. Matt Pulisic
Mr. Matt Pulisic
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas Zindrick, J.D.
Mr. Thomas Zindrick, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
653.29K
+123.66%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
502.78K
+4.64%
Dr. Joseph Cappello, Ph.D.
Dr. Joseph Cappello, Ph.D.
Chief Technical Officer
Chief Technical Officer
138.02K
+352.27%
Ms. Mary Mirabelli
Ms. Mary Mirabelli
Independent Director
Independent Director
74.28K
+42.85%
Mr. John W. Smither
Mr. John W. Smither
Independent Director
Independent Director
70.38K
+46.33%
Mr. James L. (Jim) Tyree
Mr. James L. (Jim) Tyree
Lead Independent Director
Lead Independent Director
68.07K
+48.66%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月17日 周五
更新时间: 10月17日 周五
持股股东
股东类型
持股股东
持股股东
占比
Szalay (Aladar)
8.40%
Woodward Diversified Capital, LLC
4.88%
The Vanguard Group, Inc.
3.85%
Bleichroeder LP
1.89%
Zindrick (Thomas)
1.73%
其他
79.25%
持股股东
持股股东
占比
Szalay (Aladar)
8.40%
Woodward Diversified Capital, LLC
4.88%
The Vanguard Group, Inc.
3.85%
Bleichroeder LP
1.89%
Zindrick (Thomas)
1.73%
其他
79.25%
股东类型
持股股东
占比
Investment Advisor
15.62%
Individual Investor
12.99%
Investment Advisor/Hedge Fund
2.33%
Research Firm
1.25%
Hedge Fund
1.05%
Bank and Trust
0.25%
Pension Fund
0.05%
其他
66.46%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
181
7.76M
20.55%
-2.92M
2025Q2
192
11.82M
31.32%
-605.45K
2025Q1
195
13.15M
37.48%
-1.78M
2024Q4
174
10.63M
30.79%
-4.62M
2024Q3
166
10.86M
31.45%
-4.05M
2024Q2
164
13.11M
38.15%
-670.88K
2024Q1
142
12.07M
43.82%
-1.42M
2023Q4
124
11.85M
43.27%
-65.47K
2023Q3
109
10.78M
39.96%
+2.52M
2023Q2
76
7.01M
27.00%
-28.17K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Szalay (Aladar)
3.17M
8.4%
-242.07K
-7.09%
Jun 30, 2025
Woodward Diversified Capital, LLC
1.78M
4.71%
+317.17K
+21.71%
Jun 30, 2025
The Vanguard Group, Inc.
1.45M
3.85%
+176.90K
+13.85%
Jun 30, 2025
Bleichroeder LP
714.00K
1.89%
--
--
Jun 30, 2025
Zindrick (Thomas)
653.29K
1.73%
+361.20K
+123.66%
Aug 27, 2025
Thomas (John)
502.78K
1.33%
+22.28K
+4.64%
Aug 27, 2025
BofA Global Research (US)
408.69K
1.08%
+61.00
+0.01%
Jun 30, 2025
Geode Capital Management, L.L.C.
318.82K
0.84%
+5.60K
+1.79%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
318.07K
0.84%
+11.30K
+3.68%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
iShares Micro-Cap ETF
0.03%
iShares Russell 3000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Humankind US Stock ETF
0%
ProShares UltraPro Russell2000
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
Schwab U.S. Small-Cap ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.03%
iShares Russell 3000 ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
iShares Russell 2000 ETF
占比0%
Humankind US Stock ETF
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
Proshares Ultra Russell 2000
占比0%
Schwab U.S. Small-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
